Blog - Litchlab

EN

CN

{$ImageUrl,alt}

Blog

Home>Blog

Comprehensive Analysis of Liposome Types: Diversified Solutions for Vaccine Delivery

Comprehensive Analysis of Liposome Types: Diversified Solutions for Vaccine DeliveryLiposomes, as crucial carriers for vaccine delivery, possess unique structural and functional characteristics that enable them to meet the complex needs of various vaccines. Fr...

Breakthrough of Liposome Technology in Cancer Therapy: FDA Approval of Irinotecan Liposome for First-Line Treatment of Metastatic Pancreatic Adenocarcinoma

Breakthrough of Liposome Technology in Cancer Therapy: FDA Approval of Irinotecan Liposome for First-Line Treatment of Metastatic Pancreatic Adenocarcinoma In May 2024, the U.S. Food and Drug Administration (FDA) announced the approval of irinotecan lipos...

mRNA Vaccines and Lipid Nanoparticle Lyophilization Technology: Breakthroughs in Innovative Delivery Systems in Vaccine Development

mRNA Vaccines and Lipid Nanoparticle Lyophilization Technology: Breakthroughs in Innovative Delivery Systems in Vaccine Development Driven by the COVID-19 pandemic, mRNA vaccines and lipid nanoparticle (LNP) delivery systems have become key technologies i...

修改后.jpg

Litchlab: Redefining Liposomal Drug Delivery with Next-Generation CDMO Solutions

In the rapidly evolving therapeutic landscape, liposomal drug delivery has emerged as a vital platform for addressing complex diseases—including cancer, infectious diseases, genetic disorders, and immunotherapies. Litchlab, an innovation-driven Contract Develo...

Litchlab Unveils Comprehensive CDMO Platform for Liposomal & Nanocarrier Therapeutics: From Bench to GMP

As precision medicine continues to evolve, the demand for advanced lipid-based drug delivery systems has surged—particularly for therapies involving siRNA, mRNA, antibody-drug conjugates, radiopharmaceuticals, and targeted chemotherapeutics. In response to thi...

Litchlab Emerges as a Leading Innovator in Intelligent Liposomal Drug Delivery

As the global biopharma industry accelerates toward precision medicine, lipid-based nanocarriers have become critical enablers of targeted and controllable drug delivery. Among the next-generation biotech companies reshaping this space, Litchlab is gaining pro...

640 (2).jpg

The Future of Precision Delivery Has Arrived: Litchlab Accelerates the Clinical Translation of Liposome Technologies for Complex Disease Treatment

Background Research: RGD-Modified Smart Liposome Systems Break Through in Tumor TherapyIn 2025, Science Advances published a groundbreaking study revealing that PEGylated liposomes modified with RGD peptides significantly enhanced penetration and cellular upta...

640 (8).png

Litchlab’s ADC Delivery Technology: Advancing Precision Antibody-Drug Conjugates (ADCs) for Targeted Cancer Therapy

Breakthroughs in ADC Development: Precision Delivery as the Key DriverIn recent years, antibody-drug conjugates (ADCs) have emerged as a transformative class of targeted cancer therapies, leveraging advances in linker chemistry, payload stability, and optimize...

640 (7).png

Litchlab’s RDC Delivery Technology: Advancing Precision, Safety, and Efficacy in Radiopharmaceutical Drug Conjugates

Radiopharmaceutical Drug Conjugates (RDCs): The Future of Precision OncologyRadiopharmaceutical Drug Conjugates (RDCs) combine the targeting specificity of biomolecules with the potent therapeutic or diagnostic power of radionuclides, making them a promising f...

上一页 1 2 3 4 5 下一页